相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Prevention of Pediatric Respiratory Syncytial Virus Lower Respiratory Tract Illness: Perspectives for the Next Decade
Sofia S. Aranda et al.
FRONTIERS IN IMMUNOLOGY (2019)
Internal validation of Medicaid Analytic eXtract (MAX) data capture for comprehensive managed care plan enrollees from 2007 to 2010
Yan Li et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2018)
Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease
Almut G. Winterstein et al.
JAMA PEDIATRICS (2018)
1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development
Brian Maas et al.
Open Forum Infectious Diseases (2018)
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Qing Zhu et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments
Doris Makari et al.
CLINICAL PEDIATRICS (2015)
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Michael T. Brady et al.
PEDIATRICS (2014)
Validity of Laboratory-based Surveillance for Detection of Respiratory Syncytial Virus Seasons
Christian Hampp et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2013)
Appropriateness of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Moderate-Preterm Infants A Cohort Study
Almut G. Winterstein et al.
JAMA PEDIATRICS (2013)
Effectiveness of palivizumab prophylaxis in infants and children in Florida
Almut G. Winterstein et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
An algorithm to identify preterm infants in administrative claims data
Efe Eworuke et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children
Harish Nair et al.
BMC PUBLIC HEALTH (2011)
Policy Statement-Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections
Joseph A. Bocchini et al.
PEDIATRICS (2009)
Studying prescription drug use and outcomes with medicaid claims data - Strengths, limitations, and strategies
Stephen Crystal et al.
MEDICAL CARE (2007)
Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease
Nahed O. ElHassan et al.
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE (2006)
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
TF Feltes et al.
JOURNAL OF PEDIATRICS (2003)